Oppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $500.00. The company’s shares closed yesterday at $402.50.

According to TipRanks, Singh is a 5-star analyst with an average return of 9.2% and a 44.10% success rate. Singh covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Sarepta Therapeutics, and Oncternal Therapeutics.

In addition to Oppenheimer, Vertex Pharmaceuticals also received a Buy from Piper Sandler’s Christopher Raymond in a report issued today. However, on the same day, Needham maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

The company has a one-year high of $448.40 and a one-year low of $320.01. Currently, Vertex Pharmaceuticals has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals (VRTX) Company Description:

Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.